Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
Prostatic Neoplasm|Genital Neoplasms, Male|Neoplasms, Abdominal|Urogenital Neoplasms|Genital Diseases, Male|Prostatic Diseases|Antineoplastic Agents|Imatinib
DRUG: STI571 (Glivec®)
investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment., 2 - 4 weeks
investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population, continuous|investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population., continuous|To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA, continuous|To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule., continuous|To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population., continuous
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.